Evonik, University of Mainz Partner on Drug Delivery

Evonik, a specialty chemical company, and the University of Mainz have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs.
 
Evonik intends to use rPEGs for its platform of specialized lipids and commercialize the excipients under the license agreement to meet customer and market needs. Technical grade rPEG-lipids will be available in the second half of 2024.
 
By partnering with the Johannes Gutenberg University of Mainz in Germany, where rPEGs were first developed, Evonik is able to offer its customers an expanded toolbox of technologies for nucleic acid-based medicines.
 
“When scientists at the University of Mainz approached us with their groundbreaking work on rPEGs, we immediately recognized the potential for broader formulation options and the benefits this could bring our customers,” said Thomas Riermeier, head of the Health Care business line at Evonik.
 
“With Evonik, we have found an enthusiastic and experienced partner to bring rPEG-lipids globally to the pharmaceutical industry,” said Prof. Dr. Holger Frey, Johannes Gutenberg University of Mainz, who first developed rPEG polymers together with his research group.
 
Evonik’s partnership with the University of Mainz is the latest in a series of strategic steps to meet the transformative needs of the pharmaceutical industry for nucleic acid drug delivery.
 
In 2021, Evonik began a collaboration with Stanford University to scale up the synthesis and formulation of an innovative tissue-specific delivery platform for nucleic acids. Just over a year ago, Evonik opened a new cGMP facility in Hanau, Germany for the development and manufacture of smaller batches of specialized lipids. This was followed by the start of construction of a global-scale production facility for pharmaceutical specialty lipids in Lafayette, Indiana, in partnership with the U.S. Government.